Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials.
Tingting WuChenyang LvLishui WuWenjun ChenMeina LvShaojun JiangJin-Hua ZhangPublished in: Journal of neurology (2021)
All DOACs had a lower risk of ICH than VKAs. In terms of the risk of ICH, DOACs were overall as safe as LMWHs, and apixaban and dabigatran were as safe as aspirin, but rivaroxaban was not. For secondary prevention stroke, the risk of ICH with DOACs was overall lower than warfarin and similar to aspirin, but it should be noted that compared with aspirin, rivaroxaban may increase the risk of ICH. This is the first pair-wise meta-analysis that compares the risk of ICH between DOACs and other antithrombotic drugs in detail across all diseases, which may have certain significance for patients with high risk of ICH to choose antithrombotic drugs in clinical practice.
Keyphrases
- direct oral anticoagulants
- atrial fibrillation
- venous thromboembolism
- low dose
- oral anticoagulants
- systematic review
- clinical practice
- antiplatelet therapy
- percutaneous coronary intervention
- cardiovascular events
- cardiovascular disease
- type diabetes
- randomized controlled trial
- coronary artery disease
- acute coronary syndrome
- drug induced
- meta analyses
- brain injury
- subarachnoid hemorrhage
- case control